Compare LAW & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | XOMA |
|---|---|---|
| Founded | 2013 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.6M | 308.6M |
| IPO Year | 2021 | N/A |
| Metric | LAW | XOMA |
|---|---|---|
| Price | $3.79 | $33.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.00 | ★ $60.60 |
| AVG Volume (30 Days) | ★ 325.7K | 101.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,849,000.00 | N/A |
| Revenue This Year | $11.23 | $24.95 |
| Revenue Next Year | $10.60 | $6.20 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $18.40 |
| 52 Week High | $9.11 | $39.92 |
| Indicator | LAW | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 76.61 |
| Support Level | $2.45 | $32.73 |
| Resistance Level | $4.63 | $35.17 |
| Average True Range (ATR) | 0.22 | 1.68 |
| MACD | -0.02 | 0.42 |
| Stochastic Oscillator | 16.35 | 89.85 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.